BTG USA licenses transvenous lead:
This article was originally published in Clinica
Executive Summary
BTG USA says it has licensed a transvenous pacing lead to an unnamed cardiac company. The device, invented by Dr Leo Rubin of Suffern, New York, uses a helical wire to anchor the electrode near the His bundle. A second version uses retractable barbs. BTG USA, which is part of UK-based British Technology Group, acquired rights to the lead in 1992. It is patented in the US and the organisation is pursuing patent protection internationally. BTG would not name the purchaser but says it is a major supplier of cardiac care products.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.